A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions

SinusitisNasal Polyps

Interventions

DRUG

611

611 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Trial Locations (1)

Site 01, Beijing

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY

NCT06639295 - A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps | Biotech Hunter | Biotech Hunter